21-hydroxylase deficiency surgery: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{21-hydroxylase deficiency}} | ||
{{CMG}} {{AE}} {{MAD}} | {{CMG}} {{AE}} {{MAD}} | ||
== Overview == | == Overview == | ||
Revision as of 13:43, 25 July 2017
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency surgery On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency surgery |
|
Risk calculators and risk factors for 21-hydroxylase deficiency surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Reconstructive surgery and Surgical adrenalectomy.
Surgery
Reconstructive surgery
reconstructive gynecologic surgery as adolescents or adults, including clitoroplasty and vaginoplasty.[1]
Surgical adrenalectomy
The major benefit is lowering adrenal androgen and progesterone secretion. However, It increases dependency on glucocorticoid and mineralocorticoid replacement therapy.[2]
References
- ↑ Premawardhana LD, Hughes IA, Read GF, Scanlon MF (1997). "Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience". Clin Endocrinol (Oxf). 46 (3): 327–32. PMID 9156043.
- ↑ Crocker MK, Barak S, Millo CM, Beall SA, Niyyati M, Chang R; et al. (2012). "Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia". J Clin Endocrinol Metab. 97 (11): E2084–9. doi:10.1210/jc.2012-2298. PMC 3485588. PMID 22904181.